Skip to content

RBD diagnostic research

Clinical research of Insomnograf M2 on diagnosis of REM sleep behavior disorder

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032230718
Enrollment
115
Registered
2024-03-19
Start date
2024-05-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with clinically suspected RBD "Parkinson disease" "Dementia with Lewy bodies"

Interventions

Analysis of sleep EEG, oclular/trunkal/extremities movements with InSomnoGraf M2, Nemuri-Scan, and conventional polysomnography
D017286
PSG "mobile EEG" "autonomic movement recording"

Sponsors

Saiki Shinji
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Isolated RBD (iRBD): 1. Patients with normal cognitive function (with a score of 24/30 or higher on the Mini Mental State Examination). 2. Patients without any motor function impairment. 3. Patients clinically exhibiting RBD-like symptoms (talking in their sleep, excessive body movements during sleep). 4. Patients who are strongly suspected of having clinical RBD with a score of 5/13 or higher on the RBDSQ-J questionnaire. 5. Patients whose age at the time of consent is 40 years or older but less than 80 years. 6. Patients who, after receiving sufficient explanation before participating in this study, have given written consent of their own free will with full understanding. PD-RBD: 1. Patients diagnosed as Clinically Established or Probable PD according to the Movement Disorders Society 2015 PD diagnostic criteria (Mov Disord 30:1591, 2015). 2. Patients clinically exhibiting RBD-like symptoms (talking in their sleep, excessive body movements during sleep). 3. Patients who are strongly suspected of having clinical RBD with a score of 5/13 or higher on the RBDSQ-J questionnaire. 4. Patients whose age at the time of consent is 40 years or older but less than 80 years. 5. Patients who, after receiving sufficient explanation before participating in this study, have given written consent of their own free will with full understanding. DLB-RBD: 1. Patients diagnosed as Probable DLB according to the DLB diagnostic criteria (Neurology 89:88-100, 2017). 2. Patients clinically exhibiting RBD-like symptoms (talking in their sleep, excessive body movements during sleep). 3. Patients who are strongly suspected of having clinical RBD with a score of 5/13 or higher on the RBDSQ-J questionnaire. 4. Patients whose age at the time of consent is 40 years or older but less than 80 years. 5. Patients who, after receiving sufficient explanation before participating in this study, have given written consent of their own free will with full understanding.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with sleep apnea syndrome and undergoing treatment such as CPAP, for whom wearing the examination equipment is difficult. 2. PD (Parkinson's disease) or DLB (Dementia with Lewy Bodies) patients who experience a significant reduction in the effectiveness of anti-Parkinson's medications during the night and may have difficulty communicating with healthcare providers during those times. 3. Patients who are pregnant or have the potential to become pregnant. 4. Patients with severe involuntary movements (including during sleep), making it difficult to securely wear the testing equipment. 5. Patients with significant skin lesions in the electrode attachment sites (frontal area or posterior earlobe). 6. Other patients whom the principal (coordinating) investigator deems unsuitable as study subjects.

Design outcomes

Primary

MeasureTime frame
The sensitivity of RBD diagnosis using InSomnoGraph M2 was determined with PSG-based RBD diagnosis (as defined by the criteria of the International Classification of Sleep Disorders, diagnosed when chin electromyographic activity exceeds 27% of REM sleep epochs determined in 30-second intervals) considered as the true condition.

Secondary

MeasureTime frame
1. Setting of major evaluation criteria for true positive rate, specificity, positive predictive value, negative predictive value (true positive rate (ad/bc), sensitivity (a/(a+c)), specificity (d/(b+d)), positive predictive value (a/(a+b)), negative predictive value (D/(c+d)). 2. The true condition of RBD diagnosis, as defined by PSG (diagnosed when chin electromyographic activity exceeds 27% of REM sleep epochs determined in 30-second intervals according to the International Classification of Sleep Disorders), was used to determine the true condition for RBD diagnosis using InSomnoGraph M2 + SleepSCAN. This assessment includes Setting of major evaluation criteria for true positive rate, specificity, positive predictive value, negative predictive value (true positive rate (ad/bc), sensitivity (a/(a+c)), specificity (d/(b+d)), positive predictive value (a/(a+b)), negative predictive value (D/(c+d)).

Contacts

Public ContactShinji Saiki

University of Tsukuba Hospital

ssaiki@md.tsukuba.ac.jp+81-29-853-3224

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026